Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT01246063 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT01246063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01246063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Completed
Start date
May 14, 2012
Completion date
March 23, 2018
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma